Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evazarsen Monotherapy in Mild Hypertension
NCT03714776Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2019
- Primary completion
- Nov 2019
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in essential hypertension comparing Evazarsen 80 mg with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in Plasma Angiotensinogen (AGT) at Week 7. Started Jan 2019; status: completed.
02
Drugs
evazarsen
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT03714776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03714776.